Background: Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of osteoporosis because of their age, limited physical activity, smoking, malnutrition and use of corticosteroid. Inhaled corticosteroid (IC) is used in COPD as these agents decrease the frequency of exacerbations. Objectives: To assess bone mineral density (BMD), serum osteocalcin and marker of bone turnover in patients with COPD treated with IC (Beclomethasone). Subjects & Methods: Sixty Patients with moderately severe COPD, according to the criteria of GOLD committee, under IC therapy for at least one year, were assessed clinically and by evaluation of BMD. In addition, biomarkers of bone turn over, urinary hydroxyproline, total pyridinoline, and biomarker of bone formation, serum osteocalcin, were assessed. The results were compared to 20 age and sex matched healthy individuals serving as a control group. Results: There were 28 (46.7%) male and 32 (53.3%) female patients. T-score was highly significantly lower in COPD patients in comparison to control. Osteocalcin level was significantly lower in patients than in control group (P<0.05). Urinary pyridinoline level was highly significant higher in COPD group compared with control (P≤0.001). Urinary hydroxyproline level was non significantly lower in patients than control (P=0.06). T-score was significantly inversely correlated with serum osteocalcin, and urine pyridinoline levels, while it was not significantly correlated with neither patient's age nor hydroxypyroline level. Conclusion: Regular evaluation of osteocalcin and BMD would be helpful for detecting any detrimental changes of bone in COPD patients under long term IC therapy.